Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative mFOLFIRINOX and Chemoradiation for Pancreatic Cancer
NCT01560949Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2012
- Primary completion
- Feb 2019
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2012; status: completed.
02
Drugs
fluorouraciloxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01560949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01560949.